you have problems in terms of manufacturing. for example, these companies, let s say there are better equipment that comes out or their equipment becomes outdated. they may not have as much incentive to invest in new equipment, thanks for generic, because maybe they can make more money with tradename drugs. heather: it is all interconnected and trickles down. we have an impact on the patients. we have why it is happening. what can be done to turn it around? there are a bipartisan effort to get the fda to review different obligations better. they can review them against competitive drugs. maybe there s one manufacturer for a particular medication. other applications to have competitors make the same thing? vince shortage may not be an issue. heather: make it less about monopoly. what is the possibility of that happening, and how long will it take? it is unclear. it is bipartisan with susan